alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 23




Consent of Independent Registered Accounting Firm
 
 
 
 We consent to the incorporation by reference in the Registration Statements listed below of 1st Source Corporation of our reports dated February 17, 2011, with respect to the consolidated financial statements of 1st Source Corporation and subsidiaries, and the effectiveness of internal control over financial reporting of 1st Source Corporation, included in this Annual Report (Form-10K) for the year ended December 31, 2010.
 
 
 Registration Statement No. 333-157452 on Form S-3 dated February 20, 2009
 Registration Statement No. 333-101712 on Form S-8 dated December 6, 2002
 Registration Statement No. 333-101711 on Form S-8 dated December 6, 2002
 Registration Statement No. 333-101710 on Form S-8 dated December 6, 2002
 Registration Statement No. 333-101709 on Form S-8 dated December 6, 2002
 Registration Statement No. 333-64314 on Form S-8 dated July 2, 2001
 Registration Statement No. 333-64304 on Form S-8 dated July 2, 2001
 Registration Statement No. 333-26243 on Form S-8 dated April 30, 1997
 Registration Statement No. 33-81852 on Form S-8 dated July 22, 1994
 Registration Statement No. 33-8840 on Form S-2 dated September 16, 1986
 
 
 
 
 
 
 /s/  Ernst & Young LLP
 
 
 Chicago, Illinois
 February 17, 2011
1

Resolution No. 10/22-1 

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES 

VACCINES FOR CHILDREN PROGRAM 

VACCINES TO PREVENT COVID-19 

The purpose of this resolution is to add vaccines for the prevention of COVID-19 to the VFC 

program. 

Eligible Groups

All children aged 6 months through 18 years. 

Recommended Vaccination Schedule and Intervals 

COVID-19 vaccines that are either authorized under Emergency Use Authorization (EUA) or 

approved under a Biologics License Application (BLA) are to be administered according to the 

most recent age- and vaccine-appropriate schedule included in CDC’s Interim Clinical 

Considerations for COVID-19 vaccines (https://www.cdc.gov/vaccines/covid-19/clinicalconsiderations/covid-19-vaccines-us.html). 

Recommended Dosage

Dosage information is available online at: COVID-19 Vaccines | FDA. 

Contraindications and Precautions

Contraindications and precautions are available in CDC’s Interim Clinical Considerations for 

COVID-19 vaccines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-

vaccines-us.html). 

Adopted and Effective: October 19, 2022 

This document can be found on the CDC website at: 

https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html
<TABLE> <S> <C>

<ARTICLE> 9

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                          15,876
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                 3,900
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     58,915
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                        164,340
<ALLOWANCE>                                      2,721
<TOTAL-ASSETS>                                 253,340
<DEPOSITS>                                     223,020
<SHORT-TERM>                                     2,598
<LIABILITIES-OTHER>                              2,215
<LONG-TERM>                                      3,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         7,359
<OTHER-SE>                                      15,148
<TOTAL-LIABILITIES-AND-EQUITY>                 253,340
<INTEREST-LOAN>                                  7,039
<INTEREST-INVEST>                                1,814
<INTEREST-OTHER>                                   166
<INTEREST-TOTAL>                                 9,019
<INTEREST-DEPOSIT>                               3,277
<INTEREST-EXPENSE>                               3,404
<INTEREST-INCOME-NET>                            5,615
<LOAN-LOSSES>                                      130
<SECURITIES-GAINS>                                 (2)
<EXPENSE-OTHER>                                  5,011
<INCOME-PRETAX>                                  1,533
<INCOME-PRE-EXTRAORDINARY>                       1,533
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,098
<EPS-BASIC>                                       0.52
<EPS-DILUTED>                                     0.52
<YIELD-ACTUAL>                                    5.22
<LOANS-NON>                                        495
<LOANS-PAST>                                       110
<LOANS-TROUBLED>                                    75
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 2,700
<CHARGE-OFFS>                                      140
<RECOVERIES>                                        31
<ALLOWANCE-CLOSE>                                2,721
<ALLOWANCE-DOMESTIC>                             2,721
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
No. 11-428.

#### Richard Eugene Campbell, Petitioner v. Robin M. Kocher.

565 U.S. 1093, 132 S. Ct. 847,

181 L. Ed. 2d 549,

2011 U.S. LEXIS 8861.

December 12, 2011.

Petition for writ of certiorari to the Supreme Court of Virginia denied.

Same case below, 282 Va. 113, 712 S.E.2d 477.
To determine your personal computer or server MAC address, open a run window (Windows Logo key + 

R). Then type cmd /k ipconfig /all (note the three spaces) and press enter

The ‘physical address’ listed is the ‘MAC address’, which is made up of 6 groups of 2 hexadecimal 

characters (e.g. 00-21-70-BE-C6-71).
<PAGE>

Exhibit 99.1


                        CERTIFICATION OF CEO PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


    In connection with the Quarterly Report of Cyber Public Relations, Inc. (the
    "Company") on Form 10-QSB for the period ending March 31, 2003 as filed with
    the Securities and Exchange Commission on the date hereof (the "Report"),
    Maria Trinh, as President and Chief Executive Officer of the Company,
    certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
    Section 906 of the Sarbanes-Oxley Act of 2002, to the best of her knowledge,
    that:

    (1)  The Report fully complies with the requirements of section 13(a) of the
         Securities Exchange Act of 1934; and

    (2)  The information contained in the Report fairly presents, in all
         material respects, thefinancial condition and result of operations of
         the Company.


By:  /s/ Maria Trinh
--------------------

Maria Trinh
President and CEO
May 14, 2003
No. 11-7171.

#### Patricia Isabelle Hewlett, Petitioner v. Janina M. Elder.

565 U.S. 1109, 132 S. Ct. 1074,

181 L. Ed. 2d 731,

2012 U.S. LEXIS 179.

January 9, 2012.

Motion of petitioner for leave to proceed in forma pauperis denied. Petitioner is allowed until January 30, 2012, within which to pay the docketing fee required by Rule 38(a) and to submit a petition in compliance with Rule 33.1 of the Rules of this Court. Justice Breyer took no part in the consideration or decision of this motion.
Recommended updated (2023–2024 Formula) COVID-19 vaccines for 

people who ARE moderately or severely immunocompromised*† 6 MONTHS–4 YEARS

COVID-19 vaccine 

dose(s) received 

before availability 

of updated (2023–

2024 Formula) 

COVID-19 vaccines

Recommendations 

for updated 

(2023–2024 

Formula) 

vaccine, by 

manufacturer

5–11 YEARS

COVID-19 vaccine 

dose(s) received 

before availability 

of updated (2023–

2024 Formula) 

COVID-19 vaccines

Recommendations 

for updated 

(2023–2024 

Formula) 

vaccine, by 

manufacturer

12 YEARS AND OLDER

COVID-19 vaccine 

dose(s) received 

before availability 

of updated (2023–

2024 Formula) 

COVID-19 vaccines

Recommendations for 

updated 

(2023–2024 

Formula) 

vaccine, by 

manufacturer

Unvaccinated Vaccinated

Unvaccinated

Unvaccinated

* For information about administration intervals, children who transition from age 4 years to age 5 years or age 11 years to age 12 years during an mRNA vaccination series, and administration of 

additional dose(s), see Table 2 in Interim Clinical Considerations for Use of COVID-19 Vaccines. † COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Original 

monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in 

combination with any mRNA or Original monovalent Novavax vaccine doses.

3 or more 

doses any 

Moderna

2 doses any 

Moderna

1 dose any 

Moderna

1 dose any 

PfizerBioNTech

2 doses

any PfizerBioNTech

3 or more 

doses any 

PfizerBioNTech

2023–2024

Moderna

3 doses

2023–2024

PfizerBioNTech

3 doses

2023–2024

Moderna

3 doses

2023–2024

PfizerBioNTech

3 doses

2023–2024 OR

Moderna

3 doses

2023–2024

PfizerBioNTech

3 doses

2023–2024

Moderna

1 dose

2023–2024

PfizerBioNTech

1 dose

2023–2024

Moderna

1 dose

2023–2024

PfizerBioNTech

1 dose

2023–2024

Moderna

1 dose

2023–2024

PfizerBioNTech

2 doses

2023–2024

PfizerBioNTech

1 dose

2023–2024

Moderna

2 doses

Vaccinated

Vaccinated

2 doses

any 

Moderna

2 doses

any 

Moderna

1 dose

any 

Moderna

1 dose

any 

Moderna

1 dose

any PfizerBioNTech

1 dose

any PfizerBioNTech

2 doses

any PfizerBioNTech

2 doses

any PfizerBioNTech

3 or more doses 

any mRNA vaccine

3 or more 

doses any 

mRNA 

vaccine

2023–2024

Moderna

2 doses

2023–2024

Moderna

2 doses

2023–2024

Moderna

1 dose

2023–2024

Moderna

1 dose

2023–2024

PfizerBioNTech

2 doses

2023–2024

PfizerBioNTech

2 doses

2023–2024

PfizerBioNTech

1 dose

2023–2024

PfizerBioNTech

1 dose

1 or more doses 

Novavax or Janssen, 

including in 

combination with any 

Original monovalent 

or bivalent COVID-19 

vaccine doses

2023–2024

Novavax

2 doses

2023–2024

Novavax

1 dose

OR OR OR OR

OR OR

OR

See page 2 for explanation of graphic on page 1.

10/13/23 Centers for Disease Control and Prevention
<page>  EXHIBIT 32.01

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of Morgan Stanley Charter
Millburn L.P. (the "Partnership") on Form 10-Q for the period
ended September 30, 2003 as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), I, Jeffrey A.
Rothman, President, Demeter Management Corporation, the general
partner of the Partnership, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that, to the best of my knowledge:
(1)	The Report fully complies with the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents,
in all material respects, the financial condition and
results of operations of the Partnership.









By:    /s/Jeffrey A. Rothman

Name:		Jeffrey A. Rothman
Title:	President

Date:		November 14, 2003
<PAGE>


Exhibit 99.1


                        CERTIFICATION OF CEO PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Cyber Public Relations, Inc. (the
"Company") on Form 10-QSB for the period ending September 30, 2003 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), Maria
Trinh, as President and Chief Executive Officer of the Company, certifies,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, to the best of her knowledge, that:

(1)      The Report fully complies with the requirements of section 13(a) of the
         Securities Exchange Act of 1934; and

(2)      The information contained in the Report fairly presents, in all
         material respects, the financial condition and result of operations of
         the Company.


By:  /s/ Maria Trinh
--------------------------
Maria Trinh
President and CEO
Nobember 14, 2003
<PAGE>

                                                                     Exhibit 3.1

                            CERTIFICATE OF AMENDMENT
                       TO THE FOURTH AMENDED AND RESTATED
                          CERTIFICATE OF INCORPORATION
                              OF THEGLOBE.COM, INC.

      theglobe.com, inc., a corporation organized and existing under and by
virtue of the General Corporation Law of the State of Delaware,

      DOES HEREBY CERTIFY:

      FIRST: That the Board of Directors of said corporation, adopted a
resolution proposing and declaring advisable the following amendment to the
Fourth Amended and Restated Certificate of Incorporation of said corporation.
Section 1 of Article V of the Fourth Amended and Restated Certificate of
Incorporation of theglobe.com, inc. is hereby amended to read in its entirety as
set forth below:

      1. The management of the business and the conduct of the affairs of the
Corporation shall be vested in its Board. The number of directors which shall
constitute the whole Board shall be not less than five (5) nor more than nine
(9).

      SECOND: The foregoing amendment was duly adopted in accordance with
Section 242 of the General Corporation Law of the State of Delaware.

      In witness whereof, the undersigned, being the Chief Executive Officer of
the Corporation, has caused this Certificate of Amendment to be signed on this
10th day of August, 2001.

                                                   THEGLOBE.COM, INC.


                                                   /s/ Charles M. Peck
                                                   ----------------------------
Order issued November 14 , 2012 

In The 

Tourt of Apprats 

.Fi1tIi Distritt of &z.xa,t1 at Dallas 

No. 05-12-01437-CV 

IN RE KIELLE MCNEAL, Relator 

Original Proceeding from the Criminal District Court No. 5 

Dallas County, Texas 

Trial Court Cause No. F08-47896-L 

ORDER 

Before Justices Moseley, FitzGerald, and Myers 

Based on the Court's opinion of this date, we DISMISS relator's petition for writ of 

mandamus. We ORDER that relator bear the costs of this original proceeding.
You would do anything to

your child from cancer.

Simply getting the HPV vaccine at ages 11 or 12 can

help protect them against certain cancers later in life.

Ask your child’s doctor or nurse about the HPV vaccine.

www.cdc.gov/HPV

JANUARY 2020
No. 11-6709.

#### Gerard Ronald Louis, Petitioner v. United States.

565 U.S. 994, 132 S. Ct. 541,

181 L. Ed. 2d 379,

2011 U.S. LEXIS 7662.

October 31, 2011.

Petition for writ of certiorari of the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 437 Fed. Appx. 227.
(1) Adjusting Price $27.23 CWT

(2) Base Price $27.97 CWT

(3) Change from Base Price per CWT (0.74)

(4) Price change per gallon ($0.06)

(Line (3) divide by 11.63 gallons/cwt)

(5) Price change per half gallon ($0.03)

Price change per quart ($0.02) 

Price change per pint ($0.01)

Price change per 14-oz pg. ($0.01)

Price change per 12-oz pg. ($0.01)

Price change per 1/3 qt. (10-oz) ($0.00)

Price change per half pint ($0.00)

(6) Price adjustment per gallon ($0.06)

Price adjustment per half gallon ($0.03)

Price adjustment per quart ($0.02)

Price adjustment per pint ($0.01)

Price change per 14-oz pg. ($0.01)

Price change per 12-oz pg. ($0.01)

Price adjustment per 1/3 qt. (10-oz) ($0.00)

Price adjustment per half pint ($0.00)

NOTE: Numbers in brackets are negative or decreases, all others are positive or increases.

Monthly EPA Calculation for Class I Milk (Clause 52.216-9032 Alt. I)

Based on California Marketing Area Federal Milk Order #51

 Effective Date: Aug 7th, 2022
[Federal Register Volume 63, Number 145 (Wednesday, July 29, 1998)]
[Notices]
[Page 40527]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-20179]


=======================================================================
-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM


Change in Bank Control Notices; Acquisitions of Shares of Banks 
or Bank Holding Companies

    The notificants listed below have applied under the Change in Bank 
Control Act (12 U.S.C. 1817(j)) and Sec.  225.41 of the Board's 
Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. 
The factors that are considered in acting on the notices are set forth 
in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).
    The notices are available for immediate inspection at the Federal 
Reserve Bank indicated. The notices also will be available for 
inspection at the offices of the Board of Governors. Interested persons 
may express their views in writing to the Reserve Bank indicated for 
that notice or to the offices of the Board of Governors. Comments must 
be received not later than August 12, 1998.
    A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice 
President) 411 Locust Street, St. Louis, Missouri 63102-2034:
    1. Cyrus A. Ansary, Longboat Key, Florida; to retain voting shares 
of Fort Knox National Bancorp, Inc., Elizabethtown, Kentucky, and 
thereby indirectly retain voting shares of Fort Knox National Bank, 
Radcliff, Kentucky.

    Board of Governors of the Federal Reserve System, July 23, 1998.
Robert deV. Frierson,
Associate Secretary of the Board.
[FR Doc. 98-20179 Filed 7-28-98; 8:45 am]
BILLING CODE 6210-01-F
I 

116TH CONGRESS 

1ST SESSION H. R. 3468 

To amend the Fair Labor Standards Act of 1938 to provide that sex includes 

sexual orientation and gender identity, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 25, 2019 

Mr. BROWN of Maryland (for himself, Mr. CICILLINE, Mr. CRIST, Ms. MOORE, 

Ms. NORTON, Ms. HAALAND, Ms. SCHAKOWSKY, Mr. SOTO, and Ms. 

CRAIG) introduced the following bill; which was referred to the Committee 

on Education and Labor 

A BILL 

To amend the Fair Labor Standards Act of 1938 to provide 

that sex includes sexual orientation and gender identity, 

and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Fair Pay for All Act 

5 of 2019’’. 

6 SEC. 2. SEX TO INCLUDE SEXUAL ORIENTATION AND GEN7 DER IDENTITY. 

8 Section 6(d)(4) of the Fair Labor Standards Act of 

9 1938 (29 U.S.C. 206(d)(4)) is amended— 


pbinns on DSK79D2C42PROD with BILLS
2 

•HR 3468 IH

1 (1) by striking the period at the end and insert2 ing a semicolon; 

3 (2) by striking ‘‘subsection, the term’’ and in4 serting the following: ‘‘subsection— 

5 ‘‘(A) the term’’; and 

6 (3) by adding at the end the following: 

7 ‘‘(B) the term ‘gender identity’ means the gen8 der-related identity, appearance, mannerisms, or 

9 other gender-related characteristics of an individual, 

10 regardless of the individual’s designated sex at birth; 

11 ‘‘(C) the term ‘sex’ includes— 

12 ‘‘(i) a sex stereotype; 

13 ‘‘(ii) pregnancy, childbirth, or a related 

14 medical condition; 

15 ‘‘(iii) sexual orientation or gender identity; 

16 and 

17 ‘‘(iv) sex characteristics, including intersex 

18 traits; and 

19 ‘‘(D) the term ‘sexual orientation’ includes ho20 mosexuality, heterosexuality, and bisexuality.’’. 

Æ 


pbinns on DSK79D2C42PROD with BILLS
# Publicatieblad C 402A/19 o

| | ISSN 1977-0995 |
| --- | --- |
| Publicatieblad
  van de Europese Unie | C 402A |
| | |
| Uitgave in de Nederlandse taal | Mededelingen en bekendmakingen | 65e jaargang19 oktober 2022 |

ISSN 1977-0995

Publicatieblad

van de Europese Unie

C 402A

Uitgave in de Nederlandse taal

Mededelingen en bekendmakingen

65e jaargang19 oktober 2022

---

| Inhoud | Bladzijde |
| --- | --- |
| | V   Bekendmakingen |
| | BESTUURLIJKE PROCEDURES |
| | Europees Bureau voor personeelsselectie (EPSO) |
| 2022/C 402 A/01 | Aankondiging van wijziging van het addendum bij de aankondiging van de vergelijkende onderzoeken — EPSO/AD/375/20 — Juristen-linguïsten (AD 7) voor het Deens (DA) — EPSO/AD/376/20 — Juristen-linguïsten (AD 7) voor het Grieks (EL) — EPSO/AD/377/20 — Juristen-linguïsten (AD 7) voor het Frans (FR) — EPSO/AD/378/20 — Juristen-linguïsten (AD 7) voor het Kroatisch (HR) — EPSO/AD/379/20 — Juristen-linguïsten (AD 7) voor het Pools (PL) ( PB C 444 A van 22.12.2020 ) | 1 |

Inhoud

Bladzijde

V   Bekendmakingen

BESTUURLIJKE PROCEDURES

Europees Bureau voor personeelsselectie (EPSO)

2022/C 402 A/01

Aankondiging van wijziging van het addendum bij de aankondiging van de vergelijkende onderzoeken — EPSO/AD/375/20 — Juristen-linguïsten (AD 7) voor het Deens (DA) — EPSO/AD/376/20 — Juristen-linguïsten (AD 7) voor het Grieks (EL) — EPSO/AD/377/20 — Juristen-linguïsten (AD 7) voor het Frans (FR) — EPSO/AD/378/20 — Juristen-linguïsten (AD 7) voor het Kroatisch (HR) — EPSO/AD/379/20 — Juristen-linguïsten (AD 7) voor het Pools (PL) ( PB C 444 A van 22.12.2020 )

( PB C 444 A van 22.12.2020 )

1

---

| NL | |
| --- | --- |

NL

---

V Bekendmakingen

BESTUURLIJKE PROCEDURES

Europees Bureau voor personeelsselectie (EPSO)

| 19.10.2022 | NL | Publicatieblad van de Europese Unie | CA 402/1 |
| --- | --- | --- | --- |

19.10.2022

NL

Publicatieblad van de Europese Unie

CA 402/1

---

Aankondiging van wijziging van het addendum bij de aankondiging van de vergelijkende onderzoeken — EPSO/AD/375/20 — Juristen-linguïsten (AD 7) voor het Deens (DA) — EPSO/AD/376/20 — Juristen-linguïsten (AD 7) voor het Grieks (EL) — EPSO/AD/377/20 — Juristen-linguïsten (AD 7) voor het Frans (FR) — EPSO/AD/378/20 — Juristen-linguïsten (AD 7) voor het Kroatisch (HR) — EPSO/AD/379/20 — Juristen-linguïsten (AD 7) voor het Pools (PL) (1)

(
  Publicatieblad van de Europese Unie C 444 A van 22 december 2020
  )

(2022/C 402 A/01)

Op bladzijde 7 wordt na de laatste alinea van punt 6 de volgende alinea toegevoegd:

| “7. | In afwijking van punt 6 zal voor de vergelijkende onderzoeken EPSO/AD/376/20, EPSO/AD/377/20 en EPSO/AD/379/20 de procedure voor het SCBI (situationeel gedragsgericht interview) bestaan uit een onlinegesprek met twee juryleden. Zij nemen het interview af, observeren en beoordelen uw prestaties en geven een score voor de geteste competenties. Behalve de juryleden zal geen interviewer aanwezig zijn. De overige bepalingen van punt 6 blijven van toepassing.”. |
| --- | --- |

“7.

---

(1)  PB C 72 A, van 5.3.2020.

1

---